4.7 Article

Impact of Body Weight and Extreme Obesity on the Presentation, Treatment, and In-Hospital Outcomes of 50,149 Patients With ST-Segment Elevation Myocardial Infarction

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 58, 期 25, 页码 2642-2650

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2011.09.030

关键词

extreme obesity; obesity; outcomes; quality of care; STEMI

资金

  1. American College of Cardiology Foundation's National Cardiovascular Data Registry (NCDR)
  2. Society of Chest Pain Centers
  3. American College of Emergency Physicians
  4. Society of Hospital Medicine
  5. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership
  6. Beckman Coulter and Nanosphere
  7. Daichii Sankyo
  8. BMS/Sanofi
  9. Lilly
  10. Johnson Johnson
  11. Eli Lilly
  12. Hoffmann-La Roche
  13. Bristol-Myers Squibb
  14. Novartis
  15. American College of Cardiology
  16. KAI Pharmaceuticals
  17. Sanofi-Aventis
  18. Merck
  19. Orexigen Therapeutics
  20. Helsinn Pharmaceuticals
  21. Regeneron

向作者/读者索取更多资源

Objectives The aim of this study was to assess the impact of extreme (class III) obesity (body mass index [BMI] >= 40 kg/m(2)) on care and outcomes in patients with ST-segment elevation myocardial infarction (STEMI). Background Although its prevalence is increasing rapidly, little is known about the impact of extreme obesity on STEMI presentation, treatments, complication rates, and outcomes. Methods The relationship between BMI and baseline characteristics, treatment patterns, and risk-adjusted in-hospital outcomes was quantified for 50,149 patients with STEMI from the National Cardiovascular Data Registry (NCDR) ACTION Registry-GWTG. Results The proportions of patients with STEMI by BMI category were as follows: underweight (BMI <18.5 kg/m(2)) 1.6%, normal weight (18.5 kg/m(2) <= BMI <25 kg/m(2)) 23.5%, overweight (25 kg/m(2) <= BMI <30 kg/m(2)) 38.7%, class I obese (30 kg/m(2) <= BMI <35 kg/m(2)) 22.4%, class II obese (35 kg/m(2) <= BMI <40 kg/m(2)) 8.7%, and class III obese 5.1%. Extreme obesity was associated with younger age at STEMI presentation (median age 55 years for class III obese vs. 66 years for normal weight); a higher prevalence of diabetes, hypertension, and dyslipidemia; a lower prevalence of smoking; and less extensive coronary artery disease and higher left ventricular ejection fraction. Process-of-care measures were similar across BMI categories, including the extremely obese. Using class I obesity as the referent, risk-adjusted in-hospital mortality rates were significantly higher only for class III obese patients (adjusted odds ratio: 1.64; 95% confidence interval: 1.32 to 2.03). Conclusions Patients with extreme obesity present with STEMI at younger ages and have less extensive coronary artery disease, better left ventricular systolic function, and similar processes and quality of care. Despite these advantages, extreme obesity remains independently associated with higher in-hospital mortality. (J Am Coll Cardiol 2011;58:2642-50) (C) 2011 by the American College of Cardiology Foundation

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据